Symbols / MGX Stock $1.31 -2.96% Metagenomi Therapeutics, Inc.

Healthcare • Biotechnology • United States • NMS
MGX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Jian Irish M.B.A., Ph.D.
Exch · Country NMS · United States
Market Cap 49.32M
Enterprise Value -51.66M
Income -85.89M
Sales 22.33M
FCF (ttm) -56.28M
Book/sh 3.66
Cash/sh 3.72
Employees 119
Insider 10d —
IPO Feb 09, 2024
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.79
PEG —
P/S 2.21
P/B 0.36
P/C —
EV/EBITDA 0.59
EV/Sales -2.31
Quick Ratio 6.23
Current Ratio 6.42
Debt/Eq 28.44
LT Debt/Eq —
EPS (ttm) -2.29
EPS next Y -1.66
EPS Growth —
Revenue Growth -69.80%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-11
Earnings (prior) 2026-05-11
ROA -23.44%
ROE -49.02%
ROIC —
Gross Margin 0.00%
Oper. Margin -19.70%
Profit Margin 0.00%
Shs Outstand 37.65M
Shs Float 27.35M
Insider Own 19.25%
Instit Own 19.68%
Short Float 5.86%
Short Ratio 9.66
Short Interest 1.79M
52W High 3.95
vs 52W High -66.84%
52W Low 1.25
vs 52W Low 4.80%
Beta —
Impl. Vol. —
Rel Volume 0.69
Avg Volume 208.01K
Volume 142.88K
Target (mean) $9.33
Tgt Median $9.00
Tgt Low $7.00
Tgt High $12.00
# Analysts 3
Recom Strong_buy
Prev Close $1.35
Price $1.31
Change -2.96%
About

Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$9.33
Mean price target
2. Current target
$1.31
Latest analyst target
3. DCF / Fair value
$-26.91
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.31
Low
$7.00
High
$12.00
Mean
$9.33

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-12 main Wells Fargo Overweight → Overweight $9
2025-08-19 reit HC Wainwright & Co. Buy → Buy $7
2025-08-15 main Chardan Capital Buy → Buy $11
2025-08-14 main Wells Fargo Overweight → Overweight $12
2025-05-15 main Chardan Capital Buy → Buy $12
2025-05-14 main Wells Fargo Overweight → Overweight $16
2025-04-03 main HC Wainwright & Co. Buy → Buy $7
2025-03-18 main Wells Fargo Overweight → Overweight $20
2024-12-10 main HC Wainwright & Co. Buy → Buy $14
2024-11-21 reit HC Wainwright & Co. Buy → Buy $7
2024-11-20 main Chardan Capital Buy → Buy $15
2024-10-15 reit HC Wainwright & Co. Buy → Buy $7
2024-09-06 reit HC Wainwright & Co. Buy → Buy $7
2024-09-05 main Chardan Capital Buy → Buy $15
2024-08-21 main HC Wainwright & Co. Buy → Buy $7
2024-08-19 main Chardan Capital Buy → Buy $15
2024-08-15 main BMO Capital Outperform → Outperform $17
2024-07-15 reit HC Wainwright & Co. Buy → Buy $10
2024-05-15 reit HC Wainwright & Co. Buy → Buy $10
2024-05-07 init HC Wainwright & Co. — → Buy $10
News
RSS: Latest MGX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-01 WAPNICK PAMELA M. Chief Financial Officer — 24,000 $0.00 $0
2026-04-01 WEIN MATTHEW General Counsel — 11,000 $0.00 $0
2026-04-01 IRISH JIAN Chief Executive Officer — 46,000 $0.00 $0
2026-03-05 WAPNICK PAMELA M. Chief Financial Officer — 1,581 $1.60 $2,530
2026-03-05 WEIN MATTHEW General Counsel — 482 $1.60 $771
2026-03-05 IRISH JIAN Chief Executive Officer — 1,607 $1.60 $2,571
2025-12-05 IRISH JIAN Chief Executive Officer — 228,462 $0.00 $0
2025-12-05 WAPNICK PAMELA M. Chief Financial Officer — 1,576 $1.77 $2,793
2025-12-05 THOMAS BRIAN C Director — 3,830 $1.77 $6,786
2025-12-05 WEIN MATTHEW General Counsel — 199 $1.77 $353
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
25.21
-51.79%
52.30
+16.84%
44.76
+160.21%
17.20
Operating Revenue
25.21
-51.79%
52.30
+16.84%
44.76
+160.21%
17.20
Operating Expense
121.22
-14.15%
141.20
+14.56%
123.25
+99.30%
61.84
Research And Development
94.43
-13.51%
109.18
+15.65%
94.40
+118.83%
43.14
Selling General And Administration
26.79
-16.33%
32.02
+11.00%
28.84
+54.24%
18.70
General And Administrative Expense
26.79
-16.33%
32.02
+11.00%
28.84
+54.24%
18.70
Other Gand A
26.79
-16.33%
32.02
+11.00%
28.84
+54.24%
18.70
Total Expenses
121.22
-14.15%
141.20
+14.56%
123.25
+99.30%
61.84
Operating Income
-96.01
-8.00%
-88.90
-13.26%
-78.49
-75.83%
-44.64
Total Operating Income As Reported
-96.01
-8.00%
-88.90
-13.26%
-78.49
-75.83%
-44.64
EBITDA
-90.70
-8.63%
-83.49
-12.40%
-74.28
-89.54%
-39.19
Normalized EBITDA
-89.40
-20.31%
-74.31
+3.69%
-77.16
-96.39%
-39.29
Reconciled Depreciation
5.32
-1.66%
5.41
+28.52%
4.21
+142.76%
1.73
EBIT
-96.01
-8.00%
-88.90
-13.26%
-78.49
-91.79%
-40.93
Total Unusual Items
-1.29
+85.93%
-9.19
-420.03%
2.87
+2953.19%
0.09
Total Unusual Items Excluding Goodwill
-1.29
+85.93%
-9.19
-420.03%
2.87
+2953.19%
0.09
Net Income
-87.87
-12.57%
-78.06
-14.36%
-68.25
-56.57%
-43.59
Pretax Income
-87.93
-5.21%
-83.57
-38.76%
-60.23
-46.81%
-41.02
Net Non Operating Interest Income Expense
9.47
-35.67%
14.72
-4.82%
15.47
+365.76%
3.32
Interest Expense Non Operating
—
—
0.00
-100.00%
0.10
Net Interest Income
9.47
-35.67%
14.72
-4.82%
15.47
+365.76%
3.32
Interest Expense
—
—
0.00
-100.00%
0.10
Interest Income Non Operating
9.47
-35.67%
14.72
-4.82%
15.47
+352.41%
3.42
Interest Income
9.47
-35.67%
14.72
-4.82%
15.47
+352.41%
3.42
Other Income Expense
-1.38
+85.27%
-9.39
-435.91%
2.80
+847.80%
0.29
Other Non Operating Income Expenses
-0.09
+56.04%
-0.21
-179.73%
-0.07
-136.82%
0.20
Gain On Sale Of Security
-1.29
+85.93%
-9.19
-420.03%
2.87
+2953.19%
0.09
Tax Provision
-0.06
+98.95%
-5.51
-168.68%
8.03
+212.46%
2.57
Tax Rate For Calcs
0.00
-98.48%
0.00
-68.57%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
-0.00
+99.79%
-0.61
-200.58%
0.60
+2953.19%
0.02
Net Income Including Noncontrolling Interests
-87.87
-12.57%
-78.06
-14.36%
-68.25
-56.57%
-43.59
Net Income From Continuing Operation Net Minority Interest
-87.87
-12.57%
-78.06
-14.36%
-68.25
-56.57%
-43.59
Net Income From Continuing And Discontinued Operation
-87.87
-12.57%
-78.06
-14.36%
-68.25
-56.57%
-43.59
Net Income Continuous Operations
-87.87
-12.57%
-78.06
-14.36%
-68.25
-56.57%
-43.59
Normalized Income
-86.58
-24.61%
-69.48
+1.48%
-70.52
-61.50%
-43.67
Net Income Common Stockholders
-87.87
-12.57%
-78.06
-14.36%
-68.25
-56.57%
-43.59
Diluted EPS
—
-2.36
-29.76%
-1.82
-25.02%
-1.45
Basic EPS
—
-2.36
-29.76%
-1.82
-25.02%
-1.45
Basic Average Shares
—
33.03
-11.99%
37.53
+25.24%
29.96
Diluted Average Shares
—
33.03
-11.99%
37.53
+25.24%
29.96
Diluted NI Availto Com Stockholders
-87.87
-12.57%
-78.06
-14.36%
-68.25
-56.57%
-43.59
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
221.10
-31.88%
324.60
-11.03%
364.84
-11.98%
414.49
Current Assets
165.54
-35.83%
257.96
-7.30%
278.27
-24.16%
366.90
Cash Cash Equivalents And Short Term Investments
160.80
-35.24%
248.31
-8.44%
271.18
-25.11%
362.13
Cash And Cash Equivalents
41.72
+52.35%
27.39
-80.52%
140.60
-23.77%
184.44
Other Short Term Investments
119.08
-46.10%
220.92
+69.19%
130.58
-26.51%
177.69
Receivables
0.30
-75.74%
1.26
-48.71%
2.45
+92.39%
1.27
Accounts Receivable
0.30
-75.74%
1.26
-48.71%
2.45
0.00
Other Receivables
—
—
—
1.27
Taxes Receivable
—
—
—
0.29
Accrued Interest Receivable
—
—
—
0.26
Prepaid Assets
—
—
—
0.69
Other Current Assets
4.43
-47.19%
8.40
+80.95%
4.64
+32.80%
3.49
Total Non Current Assets
55.56
-16.62%
66.64
-23.02%
86.57
+81.92%
47.59
Net PPE
47.38
-17.82%
57.66
-11.51%
65.15
+95.90%
33.26
Gross PPE
63.34
-8.10%
68.93
-3.72%
71.59
+101.62%
35.51
Accumulated Depreciation
-15.96
-41.64%
-11.27
-75.15%
-6.43
-186.21%
-2.25
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
1.62
+14.74%
1.41
+38.06%
1.02
+167.54%
0.38
Construction In Progress
0.00
-100.00%
0.14
-93.90%
2.35
+67.33%
1.40
Other Properties
57.33
-8.99%
63.00
-2.16%
64.39
+113.27%
30.19
Leases
4.39
+0.39%
4.38
+14.20%
3.83
+8.50%
3.53
Investments And Advances
2.15
-37.51%
3.45
-67.71%
10.68
+36.77%
7.81
Non Current Deferred Assets
—
—
5.12
0.00
Non Current Prepaid Assets
—
—
0.37
-18.22%
0.45
Other Non Current Assets
6.03
+8.93%
5.54
-48.46%
10.74
+76.85%
6.07
Total Liabilities Net Minority Interest
62.51
-30.35%
89.74
-82.07%
500.43
+2.35%
488.91
Current Liabilities
22.93
-38.53%
37.31
-45.82%
68.86
+41.87%
48.54
Payables And Accrued Expenses
3.21
-10.94%
3.61
-61.05%
9.27
+23.25%
7.52
Payables
1.49
+179.36%
0.53
-89.46%
5.06
+42.57%
3.55
Accounts Payable
1.49
+179.36%
0.53
-70.24%
1.79
-10.94%
2.01
Current Accrued Expenses
1.73
-43.92%
3.08
-26.92%
4.21
+5.99%
3.97
Pensionand Other Post Retirement Benefit Plans Current
4.99
-6.58%
5.35
-26.39%
7.26
+50.72%
4.82
Total Tax Payable
—
0.00
-100.00%
3.27
+112.63%
1.54
Income Tax Payable
—
0.00
-100.00%
3.27
+112.63%
1.54
Current Debt And Capital Lease Obligation
6.03
+7.74%
5.59
+63.17%
3.43
+126.20%
1.51
Current Capital Lease Obligation
6.03
+7.74%
5.59
+63.17%
3.43
+126.20%
1.51
Current Deferred Liabilities
8.70
-61.78%
22.76
-53.46%
48.91
+41.00%
34.69
Current Deferred Revenue
8.70
-61.78%
22.76
-52.65%
48.07
+41.62%
33.94
Total Non Current Liabilities Net Minority Interest
39.57
-24.52%
52.43
-87.85%
431.56
-2.00%
440.38
Long Term Debt And Capital Lease Obligation
34.63
-13.82%
40.19
-10.30%
44.80
+162.68%
17.06
Long Term Debt
—
—
—
—
Long Term Capital Lease Obligation
34.63
-13.82%
40.19
-10.30%
44.80
+162.68%
17.06
Non Current Deferred Liabilities
2.99
-70.80%
10.24
-66.90%
30.93
-59.41%
76.19
Non Current Deferred Revenue
2.99
-70.80%
10.24
-66.90%
30.93
-59.41%
76.19
Other Non Current Liabilities
1.95
-2.84%
2.01
-60.43%
5.08
+391.67%
1.03
Preferred Securities Outside Stock Equity
—
0.00
-100.00%
350.76
+1.34%
346.10
Stockholders Equity
158.60
-32.47%
234.86
+273.22%
-135.58
-82.17%
-74.43
Common Stock Equity
158.60
-32.47%
234.86
+273.22%
-135.58
-82.17%
-74.43
Capital Stock
0.00
+0.00%
0.00
0.00
-100.00%
2.54
Common Stock
0.00
+0.00%
0.00
0.00
-100.00%
2.54
Preferred Stock
0.00
0.00
0.00
—
Share Issued
37.62
+0.54%
37.42
-0.29%
37.53
+0.00%
37.53
Ordinary Shares Number
37.62
+0.54%
37.42
-0.29%
37.53
+0.00%
37.53
Additional Paid In Capital
469.20
+2.64%
457.15
+4733.94%
9.46
—
Retained Earnings
-310.87
-39.40%
-223.00
-53.85%
-144.94
-89.00%
-76.69
Gains Losses Not Affecting Retained Earnings
0.26
-63.33%
0.71
+830.93%
-0.10
+64.60%
-0.27
Other Equity Adjustments
0.26
-63.33%
0.71
+830.93%
-0.10
+64.60%
-0.27
Total Equity Gross Minority Interest
158.60
-32.47%
234.86
+273.22%
-135.58
-82.17%
-74.43
Total Capitalization
158.60
-32.47%
234.86
+273.22%
-135.58
-82.17%
-74.43
Working Capital
142.60
-35.37%
220.65
+5.37%
209.41
-34.22%
318.36
Invested Capital
158.60
-32.47%
234.86
+273.22%
-135.58
-82.17%
-74.43
Total Debt
40.66
-11.19%
45.78
-5.08%
48.23
+159.70%
18.57
Capital Lease Obligations
40.66
-11.19%
45.78
-5.08%
48.23
+159.70%
18.57
Net Tangible Assets
158.60
-32.47%
234.86
+273.22%
-135.58
-82.17%
-74.43
Tangible Book Value
158.60
-32.47%
234.86
+273.22%
-135.58
-82.17%
-74.43
Limited Partnership Capital
—
—
9.46
+273.06%
2.54
Total Partnership Capital
—
—
-135.58
-82.17%
-74.43
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-88.89
+18.50%
-109.07
-19.32%
-91.41
-407.53%
29.72
Cash Flow From Continuing Operating Activities
-88.89
+18.50%
-109.07
-19.32%
-91.41
-407.53%
29.72
Net Income From Continuing Operations
-87.87
-12.57%
-78.06
-14.36%
-68.25
-56.57%
-43.59
Depreciation Amortization Depletion
5.32
-1.66%
5.41
+28.52%
4.21
+142.76%
1.73
Depreciation
5.32
-1.66%
5.41
+28.52%
4.21
+142.76%
1.73
Depreciation And Amortization
5.32
-1.66%
5.41
+28.52%
4.21
+142.76%
1.73
Other Non Cash Items
5.11
+71.11%
2.98
-13.88%
3.46
+222.03%
1.08
Stock Based Compensation
11.85
-26.85%
16.20
+134.09%
6.92
+252.80%
1.96
Asset Impairment Charge
0.50
-51.82%
1.04
+4430.43%
0.02
-91.84%
0.28
Unrealized Gain Loss On Investment Securities
1.29
-85.93%
9.19
+420.03%
-2.87
-2953.19%
-0.09
Change In Working Capital
-22.09
+62.97%
-59.67
-125.77%
-26.43
-138.03%
69.49
Change In Receivables
0.95
-20.27%
1.19
+201.44%
-1.18
+7.61%
-1.27
Changes In Account Receivables
0.95
-20.27%
1.19
+148.71%
-2.45
0.00
Change In Prepaid Assets
4.31
+285.67%
-2.32
-113.12%
-1.09
+58.68%
-2.64
Change In Payables And Accrued Expense
-0.59
+88.83%
-5.26
-260.76%
3.27
-51.74%
6.79
Change In Accrued Expense
-1.64
-83.87%
-0.89
-154.82%
1.63
-64.03%
4.53
Change In Payable
1.05
+124.11%
-4.37
-365.61%
1.65
-27.07%
2.26
Change In Account Payable
1.05
+195.30%
-1.11
-1216.67%
-0.08
-111.65%
0.72
Change In Other Working Capital
-21.10
+54.92%
-46.80
-54.48%
-30.30
-146.14%
65.66
Change In Other Current Assets
—
—
—
-0.17
Change In Other Current Liabilities
-5.67
+12.32%
-6.47
-326.22%
2.86
+200.42%
0.95
Investing Cash Flow
103.53
+217.44%
-88.16
-292.76%
45.73
+137.43%
-122.20
Cash Flow From Continuing Investing Activities
103.53
+217.44%
-88.16
-292.76%
45.73
+137.43%
-122.20
Net PPE Purchase And Sale
-0.54
+82.76%
-3.11
+68.27%
-9.81
+29.78%
-13.98
Purchase Of PPE
-0.57
+81.57%
-3.11
+68.27%
-9.81
+29.78%
-13.98
Sale Of PPE
0.04
0.00
—
—
Capital Expenditure
-0.57
+81.57%
-3.11
+68.27%
-9.81
+29.78%
-13.98
Net Investment Purchase And Sale
104.07
+222.37%
-85.04
-253.10%
55.55
+151.33%
-108.22
Purchase Of Investment
-66.41
+78.33%
-306.42
-47.25%
-208.10
+3.14%
-214.85
Sale Of Investment
170.47
-22.99%
221.38
-16.03%
263.64
+147.26%
106.63
Financing Cash Flow
-0.36
-100.42%
84.01
+8201.68%
1.01
-99.58%
239.59
Cash Flow From Continuing Financing Activities
-0.36
-100.42%
84.01
+8201.68%
1.01
-99.58%
239.59
Net Issuance Payments Of Debt
—
—
—
0.00
Issuance Of Debt
—
—
—
0.00
Long Term Debt Issuance
—
—
—
0.00
Net Long Term Debt Issuance
—
—
—
0.00
Net Common Stock Issuance
0.00
-100.00%
84.01
0.00
—
Proceeds From Stock Option Exercised
0.20
0.00
—
—
Net Other Financing Charges
-0.56
—
-3.28
—
Changes In Cash
14.28
+112.61%
-113.22
-153.49%
-44.66
-130.36%
147.12
Beginning Cash Position
32.63
-77.63%
145.85
-23.44%
190.51
+339.01%
43.40
End Cash Position
46.91
+43.76%
32.63
-77.63%
145.85
-23.44%
190.51
Free Cash Flow
-89.47
+20.25%
-112.19
-10.83%
-101.22
-742.81%
15.75
Income Tax Paid Supplemental Data
—
3.50
+55.78%
2.25
0.00
Amortization Of Securities
-3.00
+51.37%
-6.17
+27.18%
-8.47
-650.40%
-1.13
Change In Income Tax Payable
0.00
+100.00%
-3.27
-288.79%
1.73
+12.63%
1.54
Change In Tax Payable
0.00
+100.00%
-3.27
-288.79%
1.73
+12.63%
1.54
Common Stock Issuance
0.00
-100.00%
84.01
0.00
—
Issuance Of Capital Stock
0.00
-100.00%
84.01
+1856.07%
4.29
-98.21%
239.59
Net Preferred Stock Issuance
—
0.00
-100.00%
4.29
-98.21%
239.59
Preferred Stock Issuance
—
0.00
-100.00%
4.29
-98.21%
239.59
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category